Key Highlights

● Genmab's epcoritamab combination "reduced the risk of disease progression or death" versus R-CHOP alone in a Phase 3 trial.

● The study, EPCORE DLBCL-2, enrolled patients with newly diagnosed diffuse large B-cell lymphoma.

● The drug is already on the market for relapsed patients; moving to newly diagnosed patients would open a much larger market.

Genmab jumped on Monday after late-stage data showed its antibody combination with AbbVie beat the standard R-CHOP regimen alone in newly diagnosed lymphoma patients.

A clean Phase 3 win

Genmab (NASDAQ:GMAB) jumped on Monday, Oct. 5, posting one of the bigger gains among large health care names on the Nasdaq Composite. Reports showed a strong jump, though exact figures differed.

The catalyst was trial data. Genmab and partner AbbVie (NYSE:ABBV) said that adding their drug epcoritamab, sold as Epkinly, to the standard R-CHOP chemotherapy regimen "reduced the risk of disease progression or death" compared with R-CHOP alone. The Phase 3 study, called EPCORE DLBCL-2, enrolled patients with newly diagnosed diffuse large B-cell lymphoma.

Why this result matters

Diffuse large B-cell lymphoma is the most common aggressive form of non-Hodgkin lymphoma. R-CHOP, a combination of an antibody with several chemotherapy drugs, has long been the backbone of first-line treatment. Beating it in a head-to-head late-stage trial is a high bar.

Epcoritamab is a bispecific antibody, designed to bind both to cancer cells and to the body's T cells, bringing the immune system into direct contact with the tumor. It is already on the market for patients whose lymphoma has returned or stopped responding to other treatments. Moving into newly diagnosed patients would open up a much larger group of potential users.

For Genmab, a Danish biotech whose US shares trade as American depositary shares, the readout strengthens a key product at a time when investors are focused on future growth drivers. AbbVie shares the development and commercial work on the drug.

Health care was split

Genmab's rally stood out on a day when big health care was weak. The sector was the softest group at midday, with Merck, Bristol-Myers Squibb (NYSE:BMY), Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) all lower. Bristol-Myers fell after Leerink Partners downgraded it to Market Perform.

Other parts of the sector did much better. Vaxcyte (NASDAQ:PCVX) soared after its VAX-31 pneumococcal Vaccine met all primary goals in a pivotal trial, and life-science tools names Charles River Laboratories (NYSE:CRL), Thermo Fisher (NYSE:TMO) and Danaher (NYSE:DHR) climbed.

The broader market closed higher. The Nasdaq Composite rose 286.45 points to a record 27,477.31, the S&P 500 gained 51.23 points to 7,773.95, just shy of its record, and the Dow added 90.94 points to 51,267.90.

The macro backdrop

Friday's weak September jobs report, with payrolls up just 29,000, cut bets that the Federal Reserve would raise rates again in October. Traders now see roughly a one-in-four or smaller chance of an October hike. But the 10-year Treasury Yield still rose to its highest level since 2002, as Inflation worries lingered. The ISM services survey showed prices paid at the highest since July 2022.

B. Riley Wealth's Art Hogan said: "With the economic data calendar being light and Earnings about a week away, investors are really groping for anything positive to glom onto, and clearly they're looking at lower energy prices." Brent Crude settled at $100.32, down on the day.

What to watch

Investors will look for fuller detail from the EPCORE DLBCL-2 study, including how durable the benefit is and how the combination was tolerated. Any regulatory filings for first-line use would be the next milestone, though no timeline was given.

On the macro side, the Federal Reserve releases minutes from its September meeting on Wednesday, Oct. 7, at 2 p.m. ET, and its next meeting runs Oct. 27–28. Earnings season begins in earnest with PepsiCo on Thursday, Delta Air Lines on Friday and the big banks starting Oct. 13. Genmab's next Quarterly Report will offer an update on Epkinly sales.